JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GRIESEMER, E. C.
Right arrow Articles by WELLS, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GRIESEMER, E. C.
Right arrow Articles by WELLS, J. A.
Journal of Pharmacology And Experimental Therapeutics, Vol. 116, Issue 3, 282-286, 1956
Copyright © 1956 by American Society for Pharmacology and Experimental Therapeutics

ABOLITION OF EPINEPHRINE INACTIVATING PROPERTIES OF LIVER BY INHIBITORS OF MONOAMINE OXIDASE

E. C. GRIESEMER 1 and J. A. WELLS 1

1 Department of Pharmacology, Northwestern University Medical School, Chicago, Ill.

Monoamine oxidase inhibitors, iprornazid and choline-p-tolyl ether, have been shown to prevent completely the ability of liver tissue to inactivate epinephrine. No evidence is found for systems insusceptible to monoamine oxidase inhibitors which might explain the inability of such agents to potentiate biological responses to epinephrine.

Submitted on September 17, 1955






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1956 by the American Society for Pharmacology and Experimental Therapeutics.